NTM are a family of bacteria distantly related to the tuberculosis germ but not contagious person-to-person.
They live in soil and water — including municipal water systems, shower heads, hot tubs, and decorative fountains. Most people inhale NTM regularly without consequence, but in patients with vulnerable lungs or weakened immune systems, NTM can establish chronic infection.
Approximately 60–80% of patients achieve sputum culture conversion within 6 months of starting therapy. By 12 months, roughly 75–85% have converted. Patients who do not convert by 6 months represent a refractory population for whom additional therapy may be considered.
NTM is slow-moving. Patients often have symptoms for years before diagnosis: chronic cough (often dry, sometimes productive), fatigue, low-grade fevers, weight loss, and gradual decline in exercise capacity. Many patients are initially diagnosed with bronchiectasis, COPD, or chronic bronchitis before the NTM is identified.
Diagnosis requires three things: clinical signs (compatible symptoms), radiologic findings (CT showing nodular bronchiectasis or cavitary disease), and microbiologic confirmation (two or more positive sputum cultures for NTM, or one positive culture from a bronchoscopic sample). The microbiologic criteria are strict because NTM can be a colonizer (present without causing disease) — over-treatment is a real risk. We also identify the specific species: MAC, Mycobacterium abscessus, and Mycobacterium kansasii are the most common.
Treatment is long and difficult. The standard MAC regimen is a three-drug combination of azithromycin (or clarithromycin), ethambutol, and rifampin, taken for at least 12 months after sputum culture conversion — usually 18–24 months total. Mycobacterium abscessus is more resistant and often requires IV antibiotics for parts of the course. Side effects are common. Many patients also need airway clearance therapy because the underlying bronchiectasis perpetuates the infection. Newer therapies — inhaled liposomal amikacin (Arikayce) — improve outcomes in refractory disease. Not every patient with NTM needs treatment.
This page is general medical information, not personalized medical advice. If you have questions about your specific health, talk with your Nimbus clinician.
